Abivax SA (ABVX) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Abivax SA (ABVX) over the past year, gaining 98.6% versus a gain of 2.9%. Abivax SA is the larger company by market cap ($7.77 billion vs $4.91 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | TVTX |
|---|---|---|
| Share price | $89.05 | $52.04 |
| Market cap | $7.77B | $4.91B |
| 1-day change | +2.34% | -2.62% |
| YTD return | -33.97% | +36.19% |
| 1-year return | +2.94% | +98.63% |
| 5-year return | — | +112.41% |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-6.08 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $490.73M |
| Revenue growth (YoY) | — | +110.45% |
| Net income (latest FY) | — | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | — | -12.80% |
| Net margin | — | -5.21% |
| 52-week high | $148.83 | $68.73 |
| 52-week low | $69.81 | $22.59 |
| Distance from 52-week high | -40.17% | -24.28% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.17% | +44.52% |
| Average volume | 1.11M | 1.59M |
| Shares outstanding | 87.27M | 94.26M |
| Employees | 98 | 497 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed ABVX by 95.7 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Healthcare · Biotechnology · 98 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Healthcare · Biotechnology · 497 employees
ABVX vs TVTX FAQ
Which is bigger, Abivax SA or Travere Therapeutics?
Abivax SA (ABVX) is larger, with a market capitalization of $7.77B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, ABVX or TVTX?
TVTX returned +98.63% over the past 12 months, compared with +2.94% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.